Geron (GERN) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is GERN's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Geron NASDAQ: GERN is focusing on expanding U.S. use of its blood cancer drug RYTELO, preparing for a commercial sale in Germany and evaluating potential deals after discontinuing a late-stage trial in another indication…

Geron (NASDAQ: GERN - Get Free Report) and MDxHealth (NASDAQ: MDXH - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the streng…

RYTELO quarterly net product revenue rose 27% year over year. Geron discontinued its Phase III trial in relapsed myelofibrosis.…

Geron NASDAQ: GERN reported third-quarter net product revenue of $60.1 million for RYTELO, a 27% increase from $47.2 million a year earlier, as the company cited continued growth in prescribing, particularly among commun…

Geron Corporation (GERN) Q3 2026 Earnings Call Transcript…

Geron (GERN) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.03 per share a year ago.…

FOSTER CITY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people living with blood cance…

Achieved $60.1 million in RYTELO ® (imetelstat) net product revenue in Q3 2026, an increase of 5% compared to Q2 2026…

FOSTER CITY, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announce…

Geron achieved FDA approval for RYTELO (imetelstat) in June 2024, targeting lower-risk myelodysplastic syndromes (LR-MDS). RYTELO is Geron's only advanced-stage asset, marking a pivotal milestone. GERN's recent pullback …

Geron (NASDAQ: GERN - Get Free Report) is expected to post its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Geron to post earnings of ($0.01) per share and revenue of $60.36 million…

Geron Corporation (NASDAQ:GERN) shares plunged on Wednesday after the company halted its late-stage cancer program.…

Geron said on Wednesday it would discontinue a late-stage trial testing its treatment for patients with a form of rare blood cancer.…

FOSTER CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage hematology biopharmaceutical company, today announced the decision to discontinue the Phase 3 IMpactMF trial eva…

FOSTER CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announce…

FOSTER CITY, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today reported…

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket p…

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation in…

Presentations feature real-world experience and clinical evidence in lower-risk MDS, underscoring growing global scientific engagement with imetelstat FOSTER CITY, Calif. , Oct. 12, 2026 (GLOBE NEWSWIRE) -- Geron Corpora…

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket p…

NEW YORK and NEW ORLEANS, Sept. 25, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.…

FOSTER CITY, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today reporte…

Geron NASDAQ: GERN executives said the company remains on track to generate 2026 RYTELO net revenue of $220 million to $240 million, with Chief Executive Officer Harout Semerjian saying the company now expects results to…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

